F
F. Michael Yakes
Researcher at Exelixis
Publications - 14
Citations - 3840
F. Michael Yakes is an academic researcher from Exelixis. The author has contributed to research in topics: DNA damage & Receptor tyrosine kinase. The author has an hindex of 13, co-authored 14 publications receiving 3461 citations. Previous affiliations of F. Michael Yakes include University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress
TL;DR: Results indicate that mitochondrial DNA is a critical cellular target for ROS, and persistent mitochondrial DNA damage may serve as a useful biomarker for ROS-associated diseases.
Journal ArticleDOI
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes,Jason Chen,Jenny Tan,Kyoko Yamaguchi,Yongchang Shi,Peiwen Yu,Fawn Qian,Felix Chu,Frauke Bentzien,Belinda Cancilla,Jessica Orf,Andrew You,A. Douglas Laird,Stefan Engst,Lillian Lee,Justin Lesch,Yu-Chien Chou,Alison Joly +17 more
TL;DR: Treatment with cabozantinib is suggested to be a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.
Journal ArticleDOI
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Fawn Qian,Stefan Engst,Kyoko Yamaguchi,Peiwen Yu,Kwang-Ai Won,Lillian Mock,Tracy Lou,Jenny Tan,Connie Li,Danny Tam,Julie Lougheed,F. Michael Yakes,Frauke Bentzien,Wei Xu,Tal Zaks,Richard Wooster,Joel Greshock,Alison Joly +17 more
TL;DR: Data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.
Journal ArticleDOI
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
David J. Matthews,F. Michael Yakes,Jason Chen,Michele Tadano,Lester Bornheim,Douglas O. Clary,Albert Tai,Jill M. Wagner,Nicole Miller,Yong D. Kim,Scott Robertson,Louis Murray,Larry M. Karnitz +12 more
TL;DR: The in vitro and in vivo effects of EXEL-9844, a potent, orally available, and specific inhibitor of Chk1 and Chk2, in combination with gemcitabine, show that cell cycle checkpoint inhibitors may have significant clinical utility in potentiating the activity of gem citabine.
Journal ArticleDOI
In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer.
Frauke Bentzien,Marcus Zuzow,Nathan Heald,Anna Gibson,Yongchang Shi,Leanne Goon,Peiwen Yu,Stefan Engst,Wentao Zhang,Donghui Huang,Lora Zhao,Valentina Vysotskaia,Felix Chu,Rajana Bautista,Belinda Cancilla,Peter Lamb,Alison H. Joly,F. Michael Yakes +17 more
TL;DR: Cabozantinib is a potent inhibitor of RET and prevalent mutationally activated forms of RET known to be associated with MTC, and effectively inhibits the growth of a MTC tumor cell model in vitro and in vivo.